ARS Pharmaceuticals(SPRY) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SPRY ARS Pharmaceuticals

Watchlist

10.830
-0.020-0.18%

Close Mar 10 16:00 ET

10.500
-0.330-3.05%

Post 20:01 ET

1.05BMarket Cap-21.66P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Scotiabank Initiates Coverage On ARS Pharmaceuticals With Sector Outperform Rating, Announces Price Target of $30
BenzingaMar 7 17:17 ET · Ratings
Insider Sale: Director at $SPRY Sells 400 Shares
Quiver QuantitativeMar 7 17:17 ET
ARS Pharmaceuticals Analyst Ratings
BenzingaMar 7 17:16 ET · Ratings
Leerink Partners Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $27
Moomoo NewsMar 7 03:33 ET · Ratings
ARS Pharmaceuticals: Strategic Developments and Market Opportunities Drive Buy Rating for Neffy
TipRanksMar 7 02:58 ET · Ratings
Express News | ARS Pharmaceuticals Shares up 1.6% on Expanded US Approval for Allergic Reaction Nasal Spray
ReutersMar 6 09:36 ET

Comments

Jaguar8

Mar 5 19:01

🟡Watchlist, MARCH 6,2025, Thursday. NFA - DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...

Trytosaveabit

Mar 5 15:11

news

$ARS Pharmaceuticals (SPRY.US)$ Reuters
just
ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to

This_Guy

Dec 19, 2024 16:31

$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...

Green Dragon 2024

Nov 11, 2024 10:40

Additional info…

$ARS Pharmaceuticals (SPRY.US)$ comments from ALK CEO and sales projection. 🍾

Jaguar8

Nov 11, 2024 06:09

NEWS

$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...